Tan Huawei, Zhang Xueyu, Bi Shengxian, Chen Yingchun, Guo Dandan
Department of Health Management, School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Public Health. 2024 Nov 20;12:1431991. doi: 10.3389/fpubh.2024.1431991. eCollection 2024.
Controlling the growth of inpatient costs presents a major challenge in China's healthcare system. China introduced a new case-based payment method, the "Diagnosis Intervention Packet" (DIP), to address the surge in hospitalization expenses. However, the influence of DIP payment reform on cost shifting among coronary heart disease (CHD) inpatients remains unclear.
This study focused on Zunyi, a national pilot city for DIP, utilizing inpatient claim data to assess the effects of DIP payment reform. We analyzed the influence on total health expenditures (THE), individual payments excluding reimbursement (IPER), proportion of IPER, copayments for category-B, proportion of copayments for category-B, copayments for category C, and proportion of copayments for category C per case for CHD inpatient.
Results indicate a significant reduction in THE per case for CHD inpatients after the DIP reform ( = -0.1272, < 0.01). Increases in cost shifting were observed in IPER ( = 0.1080, < 0.05), the proportion of IPER ( = 0.0551, < 0.01), copayments for category B ( = 0.2392, < 0.01), and the proportion of copayments for category B ( = 0.0295, < 0.01), along with the proportion of copayments for category C ( = 0.0255, < 0.01). However, the copayments for category C did not significantly change. Notable variations in the effects of cost control and shifting were observed across different hospital categories, teaching statuses, hospital grades, and ownership types.
The DIP reform significantly reduced the THE per case for CHD inpatients, while shifting in-policy expenditures to IPER, particularly with a greater shift intensity in the proportion of Class B compared with the proportion of Class C.
控制住院费用增长是中国医疗体系面临的一项重大挑战。中国引入了一种新的按病种付费方式,即“诊断-干预组合”(DIP),以应对住院费用的激增。然而,DIP支付改革对冠心病(CHD)住院患者费用转移的影响仍不明确。
本研究聚焦于DIP国家试点城市遵义,利用住院报销数据评估DIP支付改革的效果。我们分析了其对冠心病住院患者的总医疗支出(THE)、个人自付费用(IPER)、IPER比例、乙类自付费用、乙类自付费用比例、丙类自付费用以及每例丙类自付费用比例的影响。
结果表明,DIP改革后冠心病住院患者的每例THE显著降低(=-0.1272,<0.01)。观察到IPER(=0.1080,<0.05)、IPER比例(=0.0551,<0.01)、乙类自付费用(=0.2392,<0.01)、乙类自付费用比例(=0.0295,<0.01)以及丙类自付费用比例(=0.0255,<0.01)的费用转移有所增加。然而,丙类自付费用没有显著变化。在不同医院类别、教学状况、医院等级和所有制类型中,成本控制和转移的效果存在显著差异。
DIP改革显著降低了冠心病住院患者的每例THE,同时将政策内支出转移到IPER,特别是乙类比例的转移强度大于丙类比例。